# IRF5

## Overview
IRF5, or interferon regulatory factor 5, is a gene that encodes a transcription factor involved in the regulation of immune responses. The protein product, also named IRF5, is a member of the interferon regulatory factor family and plays a crucial role in the transcriptional regulation of pro-inflammatory cytokines and type I interferons. As a transcription factor, IRF5 is primarily active in the nucleus, where it influences gene expression related to immune defense mechanisms. It is characterized by a DNA-binding domain and an IRF association domain, which are essential for its function in immune response regulation. IRF5 is involved in various cellular processes, including the activation and differentiation of immune cells, and is implicated in the pathogenesis of several autoimmune diseases due to its role in modulating inflammatory responses (Chen2008Insights; Barnes2002Multiple; Chen2010Structural).

## Structure
IRF5 is a transcription factor with a complex molecular structure that includes several distinct domains and features. The primary structure of IRF5 consists of a sequence of amino acids encoded by the IRF5 gene. The protein contains an N-terminal DNA-binding domain (DBD) and a C-terminal IRF association domain (IAD), which are crucial for its function in immune response regulation (Chen2008Insights; Chen2010Structural).

The secondary structure of IRF5 includes alpha helices and beta sheets, forming a helix-turn-helix motif within the DBD, which is essential for recognizing specific DNA sequences (Chen2010Structural). The tertiary structure of IRF5 reveals that the IAD is similar to that of IRF3, with a β-sandwich core flanked by helices and loops (Chen2010Structural).

IRF5 can form homodimers or heterodimers, indicating a quaternary structure. Dimerization is crucial for its activation and function, as it facilitates interactions with transcriptional coactivators like CBP/p300 (Chen2008Insights; Chen2010Structural). The protein undergoes post-translational modifications, such as phosphorylation at specific serine residues, which are critical for its activation and structural rearrangement (Chen2008Insights; Chen2010Structural).

IRF5 also exists in multiple isoforms due to differential splicing, which can affect its function and regulatory roles (Chen2008Insights; Chen2010Structural).

## Function
IRF5 (interferon regulatory factor 5) is a transcription factor that plays a significant role in the regulation of immune responses in healthy human cells. It is involved in the transcriptional regulation of pro-inflammatory cytokines and type I interferons, which are crucial for the body's defense against infections. IRF5 is primarily active in the nucleus, where it influences gene expression related to immune defense mechanisms (Barnes2002Multiple).

In dendritic cells, IRF5 is essential for the late-phase secretion of tumor necrosis factor (TNF), a key cytokine in immune response regulation. This process is dependent on the presence of RelA, a component of the NF-kB family, indicating a complex regulatory mechanism involving IRF5 and RelA (Krausgruber2010IRF5). IRF5 is highly expressed in monocyte-derived dendritic cells (MDDCs) and is crucial for maintaining TNF gene transcription, particularly in the later stages of immune response (Krausgruber2010IRF5).

In B cells, IRF5 acts downstream of Toll-like receptor (TLR) signaling pathways, playing a critical role in B cell activation, proliferation, and differentiation into antibody-secreting cells (ASCs). It regulates the expression of genes involved in these processes, such as MYC, and is essential for plasmablast differentiation and IgG antibody production (De2018B). IRF5's activity in B cells is regulated through nuclear translocation, which is crucial for ASC differentiation (De2018B).

## Clinical Significance
Mutations and alterations in the expression of the IRF5 gene are associated with several autoimmune diseases. Systemic lupus erythematosus (SLE) is strongly linked to polymorphisms in the IRF5 gene, such as the rs2004640 SNP, which is associated with increased IRF5 expression and elevated serum levels of IFN alpha, a key feature of SLE pathology (Eames2016Interferon; Kozyrev2007The). The IRF5 risk haplotype is also linked to a heightened interferon response signature in SLE patients, influencing inflammation and immune signaling pathways (Guthridge2012Effects).

In rheumatoid arthritis and inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, IRF5 polymorphisms contribute to disease susceptibility by altering cytokine production and promoting a proinflammatory environment (Eames2016Interferon). The rs77571059 SNP, for example, is associated with increased IRF5 expression and is linked to ulcerative colitis (Eames2016Interferon).

In hematopoietic malignancies like chronic lymphocytic leukemia (CLL) and adult T-cell leukemia/lymphoma (ATL), the IRF-5P68 mutation acts as a dominant negative regulator, inhibiting the DNA-binding activity of wild-type IRF5 and reducing pro-inflammatory cytokine production (Yang2009Functional). These findings highlight the clinical significance of IRF5 in various diseases.

## Interactions
IRF5 (interferon regulatory factor 5) is involved in various protein interactions that are crucial for its role in immune response regulation. It interacts with NF-kB RelA, forming an IRF5:RelA cistrome that targets inflammatory genes in macrophages. This interaction is facilitated by the IRF5 association domain (IAD) and the RelA dimerization domain (DD), which are essential for their functional interaction in regulating inflammatory genes (Saliba2014IRF5:RelA).

IRF5 also interacts with the COP9 signalosome (CSN) complex, which regulates its stability through the ubiquitin-proteasome pathway. The interaction occurs at both the carboxyl and amino termini of IRF5, with CSN3 identified as a direct interacting partner. This interaction is crucial for IRF5's stability and activation, as it prevents degradation and facilitates phosphorylation-induced activation (Korczeniewska2013The).

Additionally, IRF5 can form homodimers, a process essential for its activation. This dimerization is regulated by phosphorylation, which induces conformational changes that expose binding surfaces for coactivators like CBP/p300, facilitating transcriptional activation (Chen2008Insights). IRF5's interactions with other proteins and complexes underscore its pivotal role in modulating immune responses.


## References


[1. (Barnes2002Multiple) Betsy J. Barnes, Merrill J. Kellum, Ann E. Field, and Paula M. Pitha. Multiple regulatory domains of irf-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of t lymphocytes. Molecular and Cellular Biology, 22(16):5721–5740, August 2002. URL: http://dx.doi.org/10.1128/MCB.22.16.5721-5740.2002, doi:10.1128/mcb.22.16.5721-5740.2002. This article has 301 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/MCB.22.16.5721-5740.2002)

[2. (Eames2016Interferon) Hayley L. Eames, Alastair L. Corbin, and Irina A. Udalova. Interferon regulatory factor 5 in human autoimmunity and murine models of autoimmune disease. Translational Research, 167(1):167–182, January 2016. URL: http://dx.doi.org/10.1016/j.trsl.2015.06.018, doi:10.1016/j.trsl.2015.06.018. This article has 57 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.trsl.2015.06.018)

[3. (Kozyrev2007The) Sergey V. Kozyrev and Marta E. Alarcon-Riquelme. The genetics and biology of irf5-mediated signaling in lupus. Autoimmunity, 40(8):591–601, January 2007. URL: http://dx.doi.org/10.1080/08916930701510905, doi:10.1080/08916930701510905. This article has 57 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/08916930701510905)

[4. (Saliba2014IRF5:RelA) David G. Saliba, Andreas Heger, Hayley L. Eames, Spyros Oikonomopoulos, Ana Teixeira, Katrina Blazek, Ariadne Androulidaki, Daniel Wong, Fui G. Goh, Miriam Weiss, Adam Byrne, Manolis Pasparakis, Jiannis Ragoussis, and Irina A. Udalova. Irf5:rela interaction targets inflammatory genes in macrophages. Cell Reports, 8(5):1308–1317, September 2014. URL: http://dx.doi.org/10.1016/j.celrep.2014.07.034, doi:10.1016/j.celrep.2014.07.034. This article has 86 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.celrep.2014.07.034)

[5. (Korczeniewska2013The) Justyna Korczeniewska and Betsy J. Barnes. The cop9 signalosome interacts with and regulates interferon regulatory factor 5 protein stability. Molecular and Cellular Biology, 33(6):1124–1138, March 2013. URL: http://dx.doi.org/10.1128/MCB.00802-12, doi:10.1128/mcb.00802-12. This article has 18 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/MCB.00802-12)

[6. (Chen2008Insights) Weijun Chen, Suvana S Lam, Hema Srinath, Zhaozhao Jiang, John J Correia, Celia A Schiffer, Katherine A Fitzgerald, Kai Lin, and William E Royer Jr. Insights into interferon regulatory factor activation from the crystal structure of dimeric irf5. Nature Structural &amp; Molecular Biology, 15(11):1213–1220, October 2008. URL: http://dx.doi.org/10.1038/nsmb.1496, doi:10.1038/nsmb.1496. This article has 101 citations.](https://doi.org/10.1038/nsmb.1496)

[7. (Krausgruber2010IRF5) Thomas Krausgruber, David Saliba, Grigory Ryzhakov, Alessandra Lanfrancotti, Katrina Blazek, and Irina A. Udalova. Irf5 is required for late-phase tnf secretion by human dendritic cells. Blood, 115(22):4421–4430, June 2010. URL: http://dx.doi.org/10.1182/blood-2010-01-263020, doi:10.1182/blood-2010-01-263020. This article has 83 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2010-01-263020)

[8. (Guthridge2012Effects) Joel M. Guthridge, Daniel N. Clark, Amanda Templeton, Nicolas Dominguez, Rufei Lu, Gabriel S. Vidal, Jennifer A. Kelly, Kenneth M. Kauffman, John B. Harley, Patrick M. Gaffney, Judith A. James, and Brian D. Poole. Effects of irf5 lupus risk haplotype on pathways predicted to influence b cell functions. Journal of Biomedicine and Biotechnology, 2012:1–12, 2012. URL: http://dx.doi.org/10.1155/2012/594056, doi:10.1155/2012/594056. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1155/2012/594056)

[9. (Chen2010Structural) Weijun Chen and William E. Royer. Structural insights into interferon regulatory factor activation. Cellular Signalling, 22(6):883–887, June 2010. URL: http://dx.doi.org/10.1016/j.cellsig.2009.12.005, doi:10.1016/j.cellsig.2009.12.005. This article has 70 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2009.12.005)

[10. (Yang2009Functional) Long Yang, Tiejun Zhao, Xiaoliu Shi, Peyman Nakhaei, Yunling Wang, Qiang Sun, John Hiscott, and Rongtuan Lin. Functional analysis of a dominant negative mutation of interferon regulatory factor 5. PLoS ONE, 4(5):e5500, May 2009. URL: http://dx.doi.org/10.1371/journal.pone.0005500, doi:10.1371/journal.pone.0005500. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0005500)

[11. (De2018B) Saurav De, Baohong Zhang, Tiffany Shih, Sukhwinder Singh, Aaron Winkler, Robert Donnelly, and Betsy J. Barnes. B cell-intrinsic role for irf5 in tlr9/bcr-induced human b cell activation, proliferation, and plasmablast differentiation. Frontiers in Immunology, January 2018. URL: http://dx.doi.org/10.3389/fimmu.2017.01938, doi:10.3389/fimmu.2017.01938. This article has 38 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2017.01938)